Company profile: SCIEX
1.1 - Company Overview
Company description
- Provider of mass spectrometry, capillary electrophoresis, ion sources, in vitro diagnostics, HPLC and mobility spectrometry solutions for research, drug discovery and development, clinical research, and food and environmental testing. Portfolio includes Triple Quad, QTRAP, X-Series QTOF, ZenoTOF 7600, Echo MS, and TripleTOF systems supporting qualitative and quantitative analyses.
Products and services
- Echo MS Systems: Architected for high-throughput analysis with minimal sample input in mass spectrometry applications, maximizing throughput efficiency
- X-Series QTOF Systems: Benchtop systems for high-throughput data acquisition and processing in qualitative and quantitative analyses, supporting efficient mass spectrometry operations
- ZenoTOF 7600 System: High-resolution mass spectrometer integrating Zeno trap pulsing and EAD fragmentation to deliver sensitivity gains for advanced analyses
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SCIEX
Agendia
HQ: The Netherlands
Website
- Description: Provider of molecular diagnostics and personalized treatment planning for breast cancer, offering MammaPrint (70-gene analysis to assess recurrence risk, results in 6 days or less) and BluePrint (80-gene analysis to determine molecular subtype, results in less than 6 days). Supports research via the FLEX study and trials including SWOG S2206, INSIGHT, and I-SPY2.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agendia company profile →
Integrated DNA Technologies
HQ: United States
Website
- Description: Provider of custom DNA and RNA oligonucleotides with various modifications; CRISPR-Cas9 reagents and tools for genome editing; gBlocks double-stranded gene fragments (125-3000 bp) for gene assembly, qPCR, and NGS; PrimeTime qPCR probes with dye and quencher options for multiplex gene expression analysis; and xGen DNA library prep kits for next-generation sequencing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Integrated DNA Technologies company profile →
Bioline
HQ: United Kingdom
Website
- Description: Provider of fast, easy-to-use, guaranteed-to-work products developed by scientists to help customers focus on their scientific goals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioline company profile →
10x Genomics
HQ: United States
Website
- Description: Provider of an innovative genomics platform delivering spatial and single-cell multiomic solutions: Visium HD Spatial Gene Expression for whole transcriptome analysis at single cell-scale with continuous tissue coverage; Chromium Single Cell Gene Expression with multiomic options; Chromium Single Cell Immune Profiling with gene expression, cell surface proteins, and full-length paired BCR/TCR; and Xenium In Situ for subcellular single-molecule RNA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 10x Genomics company profile →
Sangamo Therapeutics
HQ: United States
Website
- Description: Provider of engineered DNA-binding protein-based therapeutics, conducting clinical trials of gene and cell therapy candidates including: giroctocogene fitelparvovec for hemophilia A; ST-920 for Fabry disease; TX200 for patients undergoing a kidney transplant; SB-525/giroctocogene fitelparvovec (Phase 1/2); and BIVV003 ex vivo cell therapy for severe sickle cell disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sangamo Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SCIEX
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SCIEX
2.2 - Growth funds investing in similar companies to SCIEX
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SCIEX
4.2 - Public trading comparable groups for SCIEX
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →